The aim of this study is to establish the safe and effective ocular delivery system of therapeutic small interfering RNA (siRNA) in corneal neovascularization therapy. The major hurdle present in siRNA-based corneal neovascularization (CNV) therapy is severe cytotoxicity caused by repetitive drug treatment. A reducible branched polyethylenimine (rBPEI)-based nanoparticle (NP) system is utilized as a new siRNA carrier as a hope for CNV therapy. The thiolated BPEI is readily self-crosslinked in mild conditions to make high molecular weight rBPEI thus allowing the creation of stable siRNA/rBPEI nanoparticles (siRNA-rBPEI-NPs). In the therapeutic region, the rBPEI polymeric matrix is effectively degraded into nontoxic LMW BPEI inside the reductive cytosol causing the rapid release of the encapsulated siRNA into the cytosol to carry out its function. The fluorescent-labeled siRNA-rBPEI-NPs can release siRNA into the entire corneal region after subconjuctival injection into the eye of Sprague Dawley rats thus confirming the proof of concept of this system. (Figure presented.).
Bibliographical noteFunding Information:
This study was funded by the GRL Project (NRF-2013K1A1A2A02050115), the GiRC (NRF-2012K1A1A2A01055811), and the Intramural Research Program of KIST. The authors greatly appreciate Mohammad Ariful Islam and Brett Tyler Sherren correcting and revising the manuscript.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
- corneal neovascularization
- ocular delivery
- reducible polyethylenimine
ASJC Scopus subject areas
- Polymers and Plastics
- Materials Chemistry